Handbook of Pharmaceutical Biotechnology

Handbook of Pharmaceutical Biotechnology pdf epub mobi txt 电子书 下载 2026

出版者:John Wiley & Sons Inc
作者:Gad, Shayne Cox 编
出品人:
页数:1680
译者:
出版时间:2007-6
价格:1701.00元
装帧:HRD
isbn号码:9780471213864
丛书系列:
图书标签:
  • Pharmaceutical Biotechnology
  • Biotechnology
  • Pharmaceuticals
  • Drug Discovery
  • Biologics
  • Recombinant DNA Technology
  • Protein Engineering
  • Vaccines
  • Gene Therapy
  • Bioprocessing
想要找书就要到 小美书屋
立刻按 ctrl+D收藏本页
你会得到大惊喜!!

具体描述

A practical overview of a full rangeof approaches to discovering, selecting, and producing biotechnology-derived drugs The Handbook of Pharmaceutical Biotechnology helps pharmaceutical scientists develop biotech drugs through a comprehensive framework that spans the process from discovery, development, and manufacturing through validation and registration. With chapters written by leading practitioners in their specialty areas, this reference: Provides an overview of biotechnology used in the drug development process Covers extensive applications, plus regulations and validation methods Features fifty chapters covering all the major approaches to the challenge of identifying, producing, and formulating new biologically derived therapeutics With its unparalleled breadth of topics and approaches, this handbook is a core reference for pharmaceutical scientists, including development researchers, toxicologists, biochemists, molecular biologists, cell biologists, immunologists, and formulation chemists. It is also a great resource for quality assurance/assessment/control managers, biotechnology technicians, and others in the biotech industry.

Handbook of Pharmaceutical Biotechnology A Comprehensive Exploration of Modern Drug Discovery and Manufacturing This exhaustive volume delves into the dynamic and rapidly evolving landscape of pharmaceutical biotechnology, offering a deep, multifaceted exploration of the principles, methodologies, and industrial applications that underpin the development of modern therapeutics. Far from being a mere compilation of facts, this handbook serves as a rigorous, systematic guide through the complex journey of transforming biological insights into marketable, life-saving medicines. The core focus of this text lies in the intersection of biology, engineering, and chemistry—the three pillars supporting contemporary biopharmaceutical development. It moves methodically from the foundational molecular biology techniques that enable target identification to the complex downstream processing required for clinical-grade product purification. Part I: Foundations and Molecular Targets The initial sections lay the groundwork by meticulously reviewing the central dogma of molecular biology as it applies to drug discovery. It examines the genetic mechanisms underlying various disease states, emphasizing the shift from small-molecule chemistry to large-molecule biologics. Gene-Based Therapeutics and Genomics: A substantial portion is dedicated to functional genomics and proteomics, detailing how high-throughput screening technologies—such as next-generation sequencing and comprehensive proteomic profiling—are utilized to identify novel disease targets. The intricacies of RNA interference (RNAi) mechanisms, antisense oligonucleotides (ASOs), and their pharmacological manipulation are thoroughly analyzed, providing an in-depth look at how nucleic acid-based drugs modulate gene expression pathways. Protein Structure and Engineering: Understanding the three-dimensional architecture of therapeutic proteins is paramount. This section provides detailed expositions on protein folding dynamics, conformational stability, and the biophysical methods (e.g., X-ray crystallography, cryo-electron microscopy) used to characterize these complex molecules. Furthermore, it extensively covers rational protein engineering—the deliberate modification of antibody complementarity-determining regions (CDRs), enzyme active sites, and scaffold stability to enhance efficacy, reduce immunogenicity, and prolong circulating half-life. The review of antibody engineering includes comprehensive chapters on monoclonal antibodies (mAbs), bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs), detailing linker chemistry and payload selection strategies. Part II: Biomanufacturing and Process Development This section transitions into the practical realities of scaling up biological production, addressing the critical challenges inherent in cultivating living systems for industrial yield. Upstream Processing: Cell Line Development and Bioreactor Operation: The engineering aspects of bioproduction receive extensive coverage. It begins with the rigorous selection and genetic modification of host cell lines—including mammalian (CHO, HEK293), microbial (E. coli, Pichia pastoris), and increasingly, insect cells—optimized for high-titer expression of the target biologic. The subsequent discussion on bioreactor technology is granular, covering the design, operation, and control of stainless steel and single-use systems. Specific attention is paid to mass transfer limitations, oxygen consumption rates, pH control strategies, and the maintenance of aseptic conditions critical for successful batch, fed-batch, and continuous perfusion cultures. The metabolic flux analysis required to maximize volumetric productivity is detailed with quantitative examples. Downstream Processing: Separation and Purification Train: The complexity of separating the desired therapeutic protein from a multitude of host cell proteins, nucleic acids, and culture media components is explored through a systematic analysis of chromatographic techniques. This includes high-resolution examination of affinity chromatography (Protein A/G), ion-exchange chromatography (IEX), and mixed-mode chromatography. Furthermore, filtration technologies, particularly tangential flow filtration (TFF) for concentration and diafiltration for buffer exchange, are treated not just as unit operations, but as integrated elements optimized for throughput and product integrity. The critical role of viral clearance validation, including nanofiltration steps, is outlined in compliance with global regulatory standards. Part III: Advanced Modalities and Emerging Technologies The final, forward-looking sections investigate the most cutting-edge areas currently reshaping the pharmaceutical landscape, focusing particularly on cell and gene therapies (CGTs). Cellular Therapies: CAR T-Cells and Beyond: This area is treated with significant depth, explaining the intricate manufacturing workflows for autologous and allogeneic cell therapies. The process of T-cell activation, genetic modification via lentiviral or retroviral vectors (or increasingly, non-integrating transposons), and ex vivo expansion protocols are dissected. Safety considerations regarding insertional mutagenesis, off-target effects, and T-cell exhaustion are discussed in detail alongside the logistical hurdles of "vein-to-vein" time management inherent in these personalized treatments. Gene Therapy Vectorology: A comprehensive review of viral vector systems—Adenovirus (AdV), Adeno-associated virus (AAV), and Lentivirus (LV)—is provided, focusing on tropism, packaging capacity, immunogenicity profiles, and large-scale vector purification challenges. Specific clinical case studies illustrating the translation of these vectors for in vivo gene editing and replacement therapies are included to ground the theoretical concepts in real-world application. mRNA Technology and Lipid Nanoparticles (LNPs): Reflecting the recent monumental shifts in vaccinology, the construction, chemical modification, and stabilization of messenger RNA (mRNA) therapeutics are analyzed. This includes the critical formulation science involved in encapsulating the fragile mRNA payload within LNPs—examining the role of ionizable lipids, helper lipids, cholesterol, and PEGylation in achieving stability, endosomal escape, and efficient cytosolic delivery. Quality, Regulatory Affairs, and Commercialization No treatment of pharmaceutical biotechnology is complete without rigorous attention to quality systems. The final chapters address Good Manufacturing Practices (GMP) compliance across the entire lifecycle, from process analytical technology (PAT) implementation for real-time monitoring to the submission requirements for Biologics License Applications (BLAs). Risk assessment frameworks, biosimilar pathway development, and intellectual property considerations surrounding novel biologic entities are also integrated into this concluding section, ensuring the reader possesses not only the scientific acumen but also the regulatory awareness necessary for successful industrial deployment. This handbook is designed for advanced students, process scientists, regulatory affairs specialists, and R&D managers seeking a unified, authoritative reference that covers the entire breadth of modern pharmaceutical biotechnology, maintaining a rigorous standard of scientific detail throughout.

作者简介

目录信息

读后感

评分

评分

评分

评分

评分

用户评价

评分

从排版和图表质量来看,这本书的设计显然没有跟上现代学术出版的水平。虽然纸张质量尚可,但内部的插图和流程图清晰度实在不敢恭维。许多关键的生化通路图和反应机制示意图,墨迹模糊,线条重叠,即便是凑近了看,也很难准确识别出关键的酶和底物。特别是那些用于展示蛋白质结构和相互作用的复杂图谱,分辨率低到令人发指,完全失去了直观解释复杂概念的能力。这在强调视觉辅助学习的当代科学读物中,是一个非常致命的缺陷。我尤其记得有一个关于抗体-药物偶联物(ADC)连接子的示意图,标注的化学结构极其拥挤,我不得不拿出放大镜才能勉强辨认出其中的关键官能团。这样的图示不仅没有帮助理解,反而增加了阅读的认知负荷,迫使读者不得不去外部资源寻找更高质量的参考图。一本如此专业的工具书,如果连最基础的图文表达质量都无法保证,那么其内容的可靠性和专业性也会在读者心中大打折扣,这简直是对读者时间和精力的极大浪费。

评分

这本书的作者团队阵容看起来非常强大,汇集了多位不同领域的专家,这本应是其优势所在,但实际上却成了内容一致性上的主要障碍。我观察到,不同章节之间的术语使用习惯和对同一概念的定义存在细微的偏差。例如,在一个关于细胞因子表达的章节中,作者使用的是“表达水平(Expression Level)”这个术语,而在另一个涉及下游纯化的章节中,却倾向于使用“产率(Yield)”来描述类似的概念,两者在严谨的生物化学语境下含义有微妙的区别。更令人困惑的是,某些基础生物学背景知识在不同作者的笔下被重复解释,但侧重点完全不同,显得信息冗余且缺乏统一的知识体系构建。这让人强烈地感觉到,这本书更像是不同专家在截稿期前匆忙地将自己的独立论文片段拼接在一起,而不是经过一个统一的、有力的主编进行整体架构和风格统筹的结果。对于需要依赖此书作为系统学习材料的初学者来说,这种内部的不协调性会造成极大的困惑,他们很难建立起一个统一、连贯的专业知识框架,因为他们接收到的信息源本身就是多中心的、缺乏整合的。

评分

我对书中涉及的监管法规和合规性部分的阐述感到非常失望。我原本以为,作为一本“生物技术”手册,它会着重分析新兴技术(如基因治疗产品、CRISPR技术在药物开发中的应用)在现有监管框架下面临的挑战和未来监管趋势的预测。然而,书中对法规的引用和分析,几乎完全停留在FDA和EMA已发布的经典指导文件的层面,对那些正在酝酿中的、尚未完全定稿的指导意见涉及甚少。当我翻到关于生物制品上市后安全监测的章节时,我发现其内容高度依赖于传统的药物警戒系统模型,对于利用大数据、人工智能等手段进行的实时、动态风险评估的讨论几乎是空白。这在当下这个技术迭代速度极快的领域,显得尤为滞后。这本书仿佛是五年前出版的,然后只是机械地更新了几个章节的页码和日期,而核心的监管哲学和技术应用前沿却未得到及时的跟进和反思。对于寻求前瞻性指导,帮助企业在快速变化的环境中制定长期战略的专业人士来说,这本书提供的法规视角略显保守和过时,缺少了那种“拥抱未来”的洞察力。

评分

这本书的封面设计极其吸引眼球,那种深邃的蓝色调配上银色的字体,给人一种专业而又前沿的感觉。我一开始是冲着这个“生物技术”的名字来的,想着里面或许会有一些关于基因编辑或者新型疫苗研发的深度内容。然而,当我翻开第一章,我发现它似乎更侧重于药剂的制剂工艺和质量控制体系的构建,对于我期待的那些分子生物学层面的突破性进展讨论得非常保守,甚至有些偏向于传统制药工业的标准操作流程解析。比如,在讲述生物大分子的纯化步骤时,作者花费了大量的篇幅来描述层析柱的装填技巧和缓冲液的配制精度,这些内容固然重要,但对于一个希望了解前沿生物技术如何驱动新药发现的读者来说,未免有些过于基础和“工程化”了。我尝试在后续章节中寻找突破口,特别是在涉及生物制剂的稳定性研究部分,希望能看到关于新型赋形剂或者冷链技术创新的讨论,但内容依旧围绕着ICH指导原则的解读展开,缺乏那种让人眼前一亮的、来自实验室一线的最新研究数据支撑。整体而言,这本书更像是一本面向制药工程师和质量保证人员的详尽操作手册,而不是一本面向生物技术研究人员的前瞻性综述。它的严谨毋庸置疑,但对于追求技术尖端的读者来说,信息密度和创新性稍显不足,更像是对既有规范的系统性梳理,而非对未来方向的探索性描绘。

评分

这本书的阅读体验称得上是一种独特的挑战,并非因为内容晦涩难懂,而是其叙事结构和逻辑推进的方式显得异常的跳跃和碎片化。例如,某一章节可能前一页还在讨论细胞培养基的优化参数,下一页便突然转向了药代动力学模型的建立,中间缺乏必要的过渡和上下文的衔接。这使得我不得不频繁地在不同章节间来回翻阅,试图拼凑出一个完整的知识图谱。我尤其想知道,作者是如何将这些看似不相关的领域串联起来的,书中似乎预设了读者已经对每个子领域都有非常扎实的背景知识,从而省略了必要的背景铺垫。举个例子,在谈及生物类似药的“可比性”评估时,作者直接引用了复杂的统计学模型公式,却未充分解释这些模型背后的生物学假设,这对于非统计学背景的读者来说,简直是一堵难以逾越的高墙。我期待的是一种循序渐进的、由浅入深的引导,帮助读者建立起对整个生物制药流程的宏观认知,但这本书给我的感觉更像是一系列高质量的、但彼此独立的讲义的松散汇编。这种结构上的缺陷极大地影响了信息吸收的效率,让原本可能清晰的知识点变得模糊不清,阅读过程充满了需要主动“脑补”的空白地带。

评分

评分

评分

评分

评分

本站所有内容均为互联网搜索引擎提供的公开搜索信息,本站不存储任何数据与内容,任何内容与数据均与本站无关,如有需要请联系相关搜索引擎包括但不限于百度google,bing,sogou

© 2026 book.quotespace.org All Rights Reserved. 小美书屋 版权所有